Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) EBT (2016 - 2025)

Historic EBT for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to -$10.6 million.

  • Aytu Biopharma's EBT fell 287068.06% to -$10.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$24.2 million, marking a year-over-year decrease of 90016.5%. This contributed to the annual value of -$13.7 million for FY2025, which is 3244.36% down from last year.
  • According to the latest figures from Q4 2025, Aytu Biopharma's EBT is -$10.6 million, which was down 287068.06% from $2.0 million recorded in Q3 2025.
  • Aytu Biopharma's EBT's 5-year high stood at $3.8 million during Q1 2025, with a 5-year trough of -$53.3 million in Q1 2022.
  • Its 5-year average for EBT is -$10.1 million, with a median of -$6.9 million in 2022.
  • Examining YoY changes over the last 5 years, Aytu Biopharma's EBT showed a top increase of 31607.24% in 2025 and a maximum decrease of 287068.06% in 2025.
  • Quarter analysis of 5 years shows Aytu Biopharma's EBT stood at -$11.6 million in 2021, then surged by 42.06% to -$6.7 million in 2022, then skyrocketed by 120.9% to $1.4 million in 2023, then tumbled by 72.69% to $382000.0 in 2024, then tumbled by 2870.68% to -$10.6 million in 2025.
  • Its EBT stands at -$10.6 million for Q4 2025, versus $2.0 million for Q3 2025 and -$19.4 million for Q2 2025.